Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.
about
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate CancerNovel tools for prostate cancer prognosis, diagnosis, and follow-upUsefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.SPINK1 protein expression and prostate cancer progression.Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancerAltered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostatesERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.Dietary lycopene intake and risk of prostate cancer defined by ERG protein expressionAn immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisImmunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer studyPre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.Precursors of prostate cancer.Diagnostic and prognostic molecular biomarkers for prostate cancer.Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.Newly available antibodies with practical applications in surgical pathology.ERG protein expression as a biomarker of prostate cancer.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a reviewIntrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.ERG expression in prostate cancer: biological relevance and clinical implication.High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.TMPRSS2-ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-analysis of Racial Differences.A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.Correlation between ERG Fusion Protein and Androgen Receptor Expression by Immunohistochemistry in Prostate, Possible Role in Diagnosis and Therapy.ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer.Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.Significantly higher expression levels of androgen receptor are associated with erythroblastosis virus E26 oncogene related gene positive prostate cancer.Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion
P2860
Q28546607-08A5230B-0274-469E-9DD8-2E7F25C5E6A7Q33625338-F84C05AD-DE15-4F4B-AD73-2A6610472177Q34036819-E0123B45-7ED4-4384-BC8D-37C6A762132FQ34203149-05A72112-1D1B-4D82-83A0-9701949275A7Q34283031-0620C7E8-1AC7-4093-9579-5D42281EF9EFQ35088099-89AE7758-6B50-4938-8D0F-0E0213F0628DQ35582540-55FC4688-743F-499A-9BF0-9A6139F181AFQ35751842-5F4AE639-F419-4C47-8232-5BF5FED01284Q36374619-7608CA7E-00F4-42AC-B9FD-BE40C0814FC3Q36606672-65B7AD33-7450-4668-A6A6-F0604BB607E4Q36610246-180452E8-6A90-4150-A9D1-356A48F9BA60Q36899790-921F04EA-E8F8-457A-BAA7-101AB082975EQ37100101-7F888FAB-BF94-4736-AAD5-FAB3438DF71DQ37174726-ED06F61D-5A95-483A-9C45-8F86429340E2Q37972697-DB5688D1-F92C-4CBE-9253-89BF55080FAFQ37972703-A71F3DE6-7D8B-4160-A9FD-B635CEF9B123Q38126854-CB95B4C8-60A1-4BB7-8378-A621619A3D4EQ38154209-AF91CD3B-7843-4779-8504-9E6FB854C3DDQ38162350-1D84405F-6BAE-4D0C-9C39-4DD248E3CD96Q38165243-C2210032-A5D2-4018-BAAE-DD282FEEB5D1Q38253055-CE9BA44D-7F86-47A9-BA94-F9A4A45EB18CQ38399291-8659DDB7-CEAA-4526-BDD4-8AEC81A439B6Q38681610-99E91384-6C76-43BC-8B9C-F51C0DF17025Q38737037-8977A47E-2189-488B-A84F-BF0C7C5998F1Q38758020-2867A9FC-2DE4-42B8-BBC0-26E14EBB7F1BQ38760532-2B51A8CE-931F-4291-9D8F-2D70BEDBBFDBQ38764526-0DAB1A9F-23E5-4E6A-A620-1641CEBB1839Q38805821-7680E4A1-B3AD-4C9C-9AB6-2B4C9F2F4D86Q39386421-C159CF9F-4864-4E8C-BE14-CB0DFE233D07Q39457666-E84E96B2-9403-43E7-8314-3B068A7BA72CQ39666134-F3ABF318-B0DB-4761-94F2-F03AA9591AD0Q40322483-1FF719DD-8B70-4A6E-8BEA-79535066B4FCQ40373848-5352B020-6C97-4B45-B75D-D97B28E99C3CQ41132392-ED1FAA78-458C-446A-8E6B-0269EB6728ABQ41192868-9C20BD80-C338-4859-884A-B885BE7321F8Q41242418-4821FA30-0306-43FD-8CCE-DF524058467BQ41916381-5DAB3CD5-D48C-4B72-B12B-7FEF0CBF9D99Q42028012-2D7D7DCA-162E-4F6F-B1FE-B3BB57F8BED2Q42116970-2F5554C0-5C8A-4E52-A638-F7328E472C3AQ42119481-558A2C5F-F71E-4819-BB51-D3B1B82978BD
P2860
Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Antibody EPR3864 is specific f ...... ons for pathological practice.
@en
Antibody EPR3864 is specific f ...... ons for pathological practice.
@nl
type
label
Antibody EPR3864 is specific f ...... ons for pathological practice.
@en
Antibody EPR3864 is specific f ...... ons for pathological practice.
@nl
prefLabel
Antibody EPR3864 is specific f ...... ons for pathological practice.
@en
Antibody EPR3864 is specific f ...... ons for pathological practice.
@nl
P2093
P2860
P1433
P1476
Antibody EPR3864 is specific f ...... ons for pathological practice.
@en
P2093
A Marije Hoogland
Anke A J W M Bressers
Cornelis J Vissers
Geert J L H van Leenders
Jan Trapman
Joost L Boormans
P2860
P2888
P304
P356
10.1038/MODPATHOL.2011.65
P577
2011-04-15T00:00:00Z